Lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF) a factor (LITAF) is a multiple functional molecule whose sequence is identical to the small integral membrane protein of the lysosome/late endosome. LITAF was initially identified as a transcription factor that activates transcription of proinflammatory cytokine in macrophages in response to LPS. Mutations of the LITAF gene are associated with a genetic disease, called Charcot-Marie-Tooth syndrome. Recently, we have reported that mRNA levels of LITAF and TNF superfamily member 15 (TNFSF15) are upregulated by 5 0 adenosine monophosphate (AMP)-activated protein kinase (AMPK). The present study further assesses their biological functions. Thus, we show that 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), a pharmacological activator of AMPK, increases the abundance of LITAF and TNFSF15 in LNCaP and C4-2 prostate cancer cells, which is abrogated by small hairpin RNA (shRNA) or the dominant-negative mutant of AMPK a1 subunit. Our data further demonstrate that AMPK activation upregulates the transcription of LITAF. Intriguingly, silencing LITAF by shRNA enhances proliferation, anchorageindependent growth of these cancer cells and tumor growth in the xenograft model. In addition, our study reveals that LITAF mediates the effect of AMPK by binding to a specific sequence in the promoter region. Furthermore, we show that TNFSF15 remarkably inhibits the growth of prostate cancer cells and bovine aortic endothelial cells in vitro, with a more potent effect toward the latter. In conjuncture, intratumoral injection of TNFSF15 significantly reduces the size of tumors and number of blood vessels and induces changes that are characteristic of tumor cell differentiation. Therefore, our studies for the first time establish the regulatory axis of AMPK-LITAF-TNFSF15 and also suggest that LITAF may function as a tumor suppressor.
Introduction
Lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF) a factor (LITAF) was initially characterized as a transcription factor that activates transcription of cytokines such as TNFa, interleukin 6, soluble TNFreceptor II (sTNF-RII) and chemokine interleukin-8 in macrophages in response to LPS (Myokai et al., 1999; Tang et al., 2006) . It was also described as a p53inducible gene (Polyak et al., 1997) . Upon stimulation, LITAF translocates to the nucleus and binds to a specific sequence of the TNFa promoter to cooperate with other transcription factors such as signal transducer and activator of transcription 6(B) to upregulate the transcription (Tang et al., 2005) . Therefore, LITAF has an important role in inflammatory response. Interestingly, the sequence of LITAF is identical to the Small Integral Membrane Protein of the Lysosome/late Endosome (SIMPLE), mutations of which are associated with a genetic disease called Charcot-Marie-Tooth disease, characterized by demyelinating disorders of the peripheral nervous system (Niemann et al., 2006) . It is not clear whether the mutations disable the transcriptional activity of LITAF or other functions.
TNF superfamily member 15 (TNFSF15) was first identified as an inhibitor of vascular endothelial cell growth factor, thus also named VEGI (Sethi et al., 2009) . This TNF subfamily contains three isoforms resulting from different splicing; the first one consists of 174 amino acids, which shares 20-30% homology to other TNF family members, and two additional isoforms comprise 192 and 251 amino acids, respectively (Sethi et al., 2009) . All the three isoforms are identical in the carboxy-terminal 151 amino acids. TNFSF15 has been shown to potently inhibit the growth of vascular endothelial cells (Yue et al., 1999; Zhai et al., 1999a) as well as tumor cells (Haridas et al., 1999) . Several tumor xenograft studies have revealed that TNFSF15 suppresses tumor growth (Zhai et al., 1999b; Pan et al., 2004; Hou et al., 2005) . In addition, the longer form, VEGI-251, also called TNF-like ligand 1, has been implicated in autoimmunity and inflammation-induced immunity (Sethi et al., 2009; Bayry, 2010) . 5 0 Adenosine monophosphate (AMP)-activated protein kinase (AMPK) is a highly conserved serine/ threonine protein kinase, consisting of three subunits, a catalytic subunit (a) and two regulatory subunits (b and g) (Hardie, 2007) . In mammals, each subunit of AMPK contains two to three isoforms (a1, a2; b1, b2; and g1, g2, g3) . AMPK serves as a fuel gauge in maintaining energy homeostasis. Thus, it is activated under metabolic stress that increases the intracellular levels of AMP, which serves as an allosteric activator by binding to the g regulatory subunit. In addition, AMPK is phosphorylated and activated by upstream kinases, such as the tumor suppressor liver kinase B 1/serine/ threonine kinase 11 (LKB1) (Hardie, 2007; Luo et al., 2010) . Under physiological conditions, AMPK is activated by hormones and cytokines, including leptin (for example, in skeletal muscle) and adiponectin secreted from adipocytes, interleukin 6, and ciliary neurotrophic factor (Zhang et al., 2009 ). In addition, AMPK can be activated by a variety of pharmacological agents. The prototypical activator is 5-aminoimidazole-4-carboxamide 1-D-ribonucleoside (AICAR), a cell-permeable agent that is phosphorylated after entering the cell and converted to ZMP (AICAR monophosphate), an AMP analog. Importantly, two clinically used anti-diabetic drugs, metformin and thiazolidinediones, have been known to activate AMPK (Zhang et al., 2009) .
Recently, we have demonstrated that inhibition of AMPK exacerbates the malignant behavior of prostate cancer cells ). In exploring the mechanism underlying the inhibitory effects of AMPK, we have identified several interesting targets, among which are LITAF and TNFSF15. In the present study, we aim to explore the relationship of these molecules with AMPK and assess their biological effects on tumor cell growth and tumor development. Our results show that AMPK activation by AICAR upregulates LITAF, which in turn increases TNFSF15 expression. All these regulations occur at the level of transcription. We further show that the knockdown of LITAF expression by shRNA enhances cell proliferation, anchorage-independent growth of prostate cancer cells and tumor development in xenograft model. Finally, we show that TNFSF15 inhibits the growth of prostate cancer cells in vitro and in vivo, with a more potent effect on endothelial cell growth and tumor angiogenesis.
Results
AMPK upregulates protein levels of LITAF Previously, we have shown that the expression of LITAF mRNA is reduced in prostate cancer cells containing the dominant negative mutant of AMPKa1 subunit or shRNA, whereas it is upregulated by AICAR treatment ). In the present study, we assessed if AMPK has a role in regulating the promoter activity of LITAF. Thus, we placed the promoter region of LITAF upstream of the firefly luciferase report gene (Tang et al., 2007) . We then transfected LNCaP cells with this plasmid together with a plasmid encoding Renilla luciferase in the presence or absence of the plasmid for the wild-type a1 subunit of AMPK. After 48 h, the cells were treated with AICAR for 8 h. Firefly luciferase activity was assayed and normalized with Renilla luciferase activity. As shown in Figure 1a , AICAR enhanced the luciferase activity by about twofold, while transfection of AMPK a1 subunit caused a 1.5-fold increase, which was further increased by the treatment with AICAR. To ascertain if the change holds true at protein levels, we treated a prostate cancer cell line, LNCaP cells, with AICAR for different periods of time and examined the expression of LITAF. As shown in Figure 1b , the treatment progressively increased the abundance of LITAF, whereas the induction was diminished in the cells expressing shRNA. A similar result was obtained with the dominant negative mutant of a1 subunit (data not shown).
LITAF inhibits the malignancy of tumor cells
To assess the biological effects of LITAF, we decided to knock down LITAF expression by shRNA. Out of four shRNA retroviral plasmids, one was found to yield 480% of the silencing effect. Thus, the retrovirus for this clone was packaged in HEK293T cells and used to (a) Promoter activity assay. LNCaP cells were transfected with a promoter-less firefly luciferase reporter plasmid (PGL3) or the plasmid with insertion of LITAF promoter region and Renilla luciferase plasmid in the presence or absence of a plasmid encoding wild-type AMPK a1 subunit. Two days later, the cells were treated with AICAR for 8 h and luciferase assay was conducted as described in Materials and methods. The luciferase activity was normalized with Renilla luciferase activity and expressed as ratios (mean ± s.d., n ¼ 3). *Po0.01 as compared with basal LITAF promoter activity. (b) LNCaP cells were stably infected with a1 shRNA or scrambled shRNA retroviruses were treated with AICAR (AI, 1 mM) for the indicated times. Cell lysates were blotted with antibodies, as indicated.
infect into LNCaP and C4-2 cells (Figure 2a ). We also included p53 shRNA as a positive control, as previous studies identified LITAF as one of the p53-induced genes. However, our current data revealed that knocking down p53 did not affect LITAF expression or its response to AICAR (data not shown). We then compared the behaviors of prostate cancer cells with or without silencing LITAF using 3-(4,5-dimethylthiazole-2,5diphenyltetrazolium bromide (MTT) assay and found that silencing LITAF significantly accelerated cell proliferation ( Figure 2b ). Furthermore, it enhanced anchorage-independent growth of prostate cancer cells on soft agars (Figure 2c ). All these effects were as great as those by knocking down p53. We then inoculated these cells into athymic nude mice and assessed tumor development. As shown in Figure 3 , our results revealed that prostate cancer cells containing LITAF shRNA form tumors at a significantly higher rate than the cells without knockdown.
LITAF mediates AMPK activation to upregulate TNFSF15
Previous studies have shown that LITAF responds to LPS to induce expression of proinflammatory cytokines such as TNFa. We have reported that AMPK activation increases expression of TNFSF15 in prostate cancer cells where TNFa is barely detectable . In this study, we were curious to ask if AICARinduced expression of TNFSF15 was mediated by LITAF. Toward this end, we treated LNCaP and C4-2 cells containing LITAF shRNA or scrambled shRNA with AICAR and analyzed mRNA abundance by quantitative PCR. The data revealed that AICAR increased levels of TNFSF15 mRNA in control cells, while the induction was markedly reduced in cells where LITAF was silenced (Figures 4a and b ). To examine if the change in mRNA levels is attributed to the regulation of transcription, we isolated 1000 bp 5 0 upstream of the transcriptional initiation site of TNFSF15 and placed it at the upstream sequence of the luciferase reporter. We then transfected the plasmid to LNcaP cells carrying scrambled or LITAF shRNA and analyzed the luciferase activity. As shown in Figure 4c , AICAR significantly stimulated the luciferase activity in control cells, whereas the stimulation was diminished by LITAF shRNA. As a putative LITAF-binding element (CTCCC) is present in the promoter region of TNFSF15 (Tang et al., 2003) , we asked if LITAF directly binds to this sequence. In the chromatin immuoprecipitation (ChIP) assay, we found that the sequence surrounding the binding element was specifically pulled down by LITAF antibody, which was increased by the treatment of LNCaP cells with AICAR.
TNFSF15 inhibits angiogenesis and tumorigenesis
To assess if TNFSF15 has a role in tumor development, we cloned cDNA encoding the longest version of TNFSF15, VEGI-251, from LNCaP cells by reverse transcription-coupled PCR and then expressed the carboxy-terminal 151 amino acids, which are identical among all three isoforms ( Figure 5 ). We then examined if the carboxy-terminal piece of TNFSF15 exerted an inhibitory effect on the growth of LNCaP cells and bovine aortic endothelial cells. In this experiment, the cells were treated with different doses of TNFSF15 for 24 and 48 h and assayed by MTT. At 24 h, the OD 570 of LNCaP cells exhibited a nearly linear increase with increasing doses of TNFSF15, reaching a maximal 20% at 1 nM (Po0.01), while at 48 h, the optical density progressively decreased with increasing doses (Po0.01). The reason for the increase in MTT readings at 24 h is not clear. It possibly reflects increased biogenesis of mitochondria within this specific time frame. In contrast, bovine aortic endothelial cells were markedly suppressed and appeared to be more sensitive to TNSF15 treatment at both 24-and 48-h points (Po0.01). Two-way analysis of variance analysis indicates that differences between different groups (cell types and times) are significant (Po0.05).
To test if TNFSF15 inhibits tumor growth in vivo, we inoculated LNCaP cells into nude mice and allowed the tumor to grow for 10 days. When tumors were palpable, intratumoral injection of TNFSF15 was performed every 2 days for 2 weeks. In the end, mice were killed and tumors removed and weighed. Our data revealed that the average weight of tumors from TNFSF15admininstered mice was half of that injected with phosphate-buffered saline vehicle (Figure 6a ). In general, tumors contained fewer visible blood vessels. To evaluate tumor vascularization, the tumor tissues were sectioned for examining histopathological morphology and immunohistochemical reactivity to the antibody for Von Willebrand Factor. As shown in Figure 6b , tumor tissues of the control animals displayed uniform and anaplastic structure without evidence of differentiation. In contrast, experimental animals exhibited multiple lobular structure surrounded and separated by connective tissue. This structure apparently manifests a likelihood of differentiated tumor. In addition, the number of blood vessels formed in the tumor tissue of the control animals was significantly more than that of the experimental animals.
Discussion
Recently, we have shown that inhibition of endogenous AMPK by expression of the dominant negative mutant of AMPK a1 subunit or its shRNA augments malignant behaviors of prostate cancer cells, whereas activation of AMPK by AICAR or introducing LKB1 to cancer cells containing loss-of-functional mutations causes changes in an opposite direction. The effects of LKB1/AMPK might be mediated by concerted actions of various downstream targets ). Among them, we have identified two novel targets, LITAF and TNFSF15. In the present study, we have demonstrated for the first time that activation of AMPK stimulates expression of LITAF, which in turns upregulates TNFSF15, and that knockdown of LITAF accelerates prostate cancer cell proliferation and tumor development. Our data also show that TNFSF15 remarkably inhibits the growth of prostate cancer cells and angiogenesis and induces morphological transition from malignant to benign tumors.
AMPK has been shown to play important roles in mediating the tumor-suppressive function of LKB1 (Xiang et al., 2004 , Luo et al., 2010 . To understand the underlying mechanisms, an exciting but challenging task is to identify new targets downstream of AMPK in addition to those well characterized, such as mTOR, FASN, p53, p27 and FOX3a (Luo et al., 2010) . In this study, we have found that AMPK regulates the transcription of LITAF, which then binds to a specific sequence in the promoter region of TNFSF15 and regulates its transcription. Currently, we do not know how AMPK regulates the transcription of LITAF. It is possible that AMPK indirectly exerts such an effect through regulation of an unidentified transcription factor. However, our data do not support that this occurs through p53. Therefore, it will be our interest to identify the transcription factor that mediates this effect.
Existing data support that LITAF is a transcription factor involved in regulating production of proinflammatory cytokines in response to LPS (Tang et al., 2005 (Tang et al., , 2006 . An additional function of LITAF relates to sorting and degradation of plasma membrane proteins by lysosome and late endosome (Niemann et al., 2006) . Mutations of LITAF/SIMPLE have been suggested to alter this second function, which may have a role in the pathogenesis of Charcot-Marie-Tooth type 1C disease (Bennett et al., 2004; Beauvais et al., 2006; Latour et al., 2006) . Thus so far, no direct evidence indicates a role of LITAF in tumorigenesis. However, several recent studies suggest that there is such a link. For instance, homozygous deletion of the LITAF gene and promoter hypermethylation are reported in some types of lymphomas (Mestre -Escorihuela et al., 2007) . Secondly, LITAF was found to associate with WW domain oxidoreductase (Ludes-Meyers et al., 2004) . The latter has been found to be altered in multiple types of cancer and its ectopic expression inhibits xenograft tumor growth of breast cancer cells (Chang et al., 2010) . Therefore, it will be interesting to assess the direct effect of LITAF on tumorigenesis and elucidate the underlying mechanisms.
Although LITAF is known to upregulate transcription of TNFa, little information has been documented on its role in regulating other TNF superfamily members. A possible link between LITAF and TNFlike ligand 1 has been suggested by the findings that their expressions are increased in macrophages of inflammatory bowel diseases such as Crohn's disease and ulcerative colitis (Stucchi et al., 2006; Young and Tovey, 2006; Picornell et al., 2007) . Interestingly, one study has so far reported that bacterially expressed chicken LITAF or LITAF expressed, secreted and purified from COS7 cells stimulates transcription of TNFSF15 in chicken macrophages (Hong et al., 2006) . This report is coincidently in line with our findings where we placed LITAF as an upstream modulator of TNFSF15 in response to AMPK activation.
A clinical investigation has indicated that high levels of TNFSF15 are associated with increased survival rate of breast cancer patients (Parr et al., 2006) . Numerous studies have reported that exogenous application of different isoforms of recombinant TNFSF15 to culture media or to animals inhibits tumor cell growth and tumor development and angiogenesis (Haridas et al., 1999; Yue et al., 1999; Zhai et al., 1999a, b; Pan et al., 2004; Hou et al., 2005) . Our present study demonstrates that bovine aorta endothelial cells are more sensitive to TNFSF15 than are LNCaP cells, which is in accord with previous reports that TNFSF15 exerts anti-tumor effects mainly through inhibition of angiogenesis (Sethi et al., 2009) . Consistently, our animal study showed that the treatment of xenograft tumors with TNFSF15 not only inhibits angiogenesis but also induces morphological changes characteristic of benign tumors.
In the end, we would emphasize that our present study has for the first time demonstrated that AMPK upregulates LITAF, which in turn increases the expression of TNFSF15. The regulation occurs at the transcriptional level. Collectively, our data suggest that LITAF and TNFSF15 may function as tumor suppressors. Therefore, we propose a model illustrated in Figure 7 . LITAF serves as one of the downstream targets of AMPK to inhibit cancer cell growth, possibly by multiple mechanisms, one of which is TNFSF15, which potently inhibits angiogenesis. As for other functions of LITAF, such as those related to lysomal/ late endosome trafficking and degradation of membrane proteins, it is worthwhile to explore if they participate in Figure 6 TNFSF15 inhibits tumor growth in xenograft model. (a) LNCaP cells were injected into nude mice as described for Figure 3 . Ten days after inoculation, intratumoral injection of TNFSF15 was performed (10 mg/ml, 100 ml for each injection) every 2 days for 2 weeks. In the end, mice were killed and tumors removed and weighed. The bars represent average weights±s.e. (n ¼ 10, Student's t test, P ¼ 0.012953). (b) Tumor tissues isolated from (a) were snap-frozen and sectioned. Histopathological morphology of tumors and immunohistochemical staining with antibodies against Von Willebrand Factor for visualizing blood vessels were examined. Two representative views from tumors injected with TNFSF15 and phosphate-buffered saline are presented. Tumor tissues of the control animals exhibited uniform and anaplastic structure without evidence of differentiation, while experimental animals exhibited multiple lobular structure surrounded and separated by connective tissue. This structure apparently indicates the likelihood of differentiated tumor. In addition, the number of blood vessels formed in the tumor tissues of the control animals was significantly more than that of the experimental animals.
Figure 7
Model of LITAF regulation of tumorigenesis. LITAF mediates the inhibitory effects of AMPK on tumorigenesis by directly regulating TNFSF15, which in turn inhibits angiogenesis, and other unidentified targets.
LITAF inhibition of tumorigenesis J Zhou et al tumorigenesis. Overall, our work points to a new direction in investigating the correlation of tumor progression and prognosis with expression levels and activity of AMPK, LITAF and TNFSF15 and the mechanism by which they are involved in tumorigenesis. Likewise, our data also suggest that targeting AMPK pathway would represent a promising approach for prevention and treatment of cancer, as it acts on both tumor cells and angiogenesis.
Materials and methods
Materials AICAR was purchased from Toronto Research Chemicals Inc. (North York, ON, Canada). Antibodies for total and phospho-T172 of the AMPK a subunit were from Cell Signaling Technology, Inc. (Danvers, MA, USA). Antibody for p53 was from Millipore (Billerica, MA, USA). Monoclonal antibodies for b-actin and flag epitope (M2) were purchased from Sigma (St Louis, MO, USA). Monoclonal antibody for LITAF was purchased from BD Biosciences (San Jose, CA, USA).
Stable cell lines
Retroviral plasmids for LITAF shRNA and scrambled shRNA were purchased from Open Biosystems (Huntsville, AL, USA). A set of four plasmids (Catalog number: RHS4529-NM_001136472) were transfected into HEK293T cells to examine a clone that produces the most efficient silencing effect and one (V2HS_247509) was selected. shRNA for p53 was obtained in pSuperRetro vector, a gift from Dr Zhixiong Xiao. Retrovirus was packaged in HEK293T cells and the virus supernatant was infected into two prostate cancer cell lines, LNCaP and C4-2. Two days after infection, the cells were selected with puromycine and maintained in RPMI1640 medium supplemented with 10% fetal bovine serum. The stable cell lines for the dominant negative mutant of human AMPK a1 catalytic subunit (D139A) and a1 shRNA were described previously .
Immunoblot
Equal amounts of cell extracts (25 mg) were separated onto SDS-PAGE and electrophoretically transferred to PVDF membranes (Millipore). The membranes were sequentially blotted with the first and second antibodies, and developed by the enhanced chemiluminescence method, according to the protocol provided by the manufacturer.
Soft agar assay for colony formation
Assays on anchorage-independent growth were carried out on soft agar, as described previously .
Expression and purification of TNFSF15
Total RNA was prepared from LNCaP cells and cDNA synthesized. TNFSF15 was amplified by PCR using the primers based on the sequence of VEGI-251 (forward: 5 0 -AT GGCCGAGGATCTGGGACTGAGC-3 0 , reverse: 5 0 -CTCTC CTCCTATAGTAAGAAGGCTCC-3 0 ) and subcloned into pCR-BluntII-TOPO (Invitrogen, Carlsbad, CA, USA). After sequencing validation, the cDNA segment encoding the carboxy-terminal 151 amino acids was amplified by PCR using the primers (forward: 5 0 -agctggatccGTTGTGAGACAA ACTCCCACACAGC-3 0 , reverse: 5 0 -agctgtcgacCTCTCCTCC TATAGTAAGAAGGCTCC-3 0 ). The PCR product was subcloned into pMal-C2 plasmid at the BamHI and SalI sites. The plasmid was transformed into JM109 cells and the recombinant TNFSF15 was induced by isopropyl b-D-1thiogalactopyranoside (IPTG), purified using Amylose beads, cleaved with Factor X, and purified further to remove Factor X, according to the manufacturer's protocol (New England BioLabs, Ipswich, MA, USA).
MTT assay
Cells (5 Â 10 3 ) were seeded into 96-well plates and cell viability was measured at different days using the MTT kit according to the manufacturer's protocol (Invitrogen).
Quantitative real-time PCR analysis
The expression of mRNA was examined by real-time PCR with the ABI 7300 Real-time PCR System (Applied Biosystems, Foster City, CA, USA), using SYBRGREEN PCR Master Mix 2 Â reagent in 20 ml reaction volume. The primers for RT-PCR were designed as described previously . Each sample was amplified in triplicate and normalized to glyceraldehyde 3-phosphate dehydrogenase expression. Results were evaluated by the comparative threshold cycle value method (2 ÀDDCt ) for relative quantification of gene expression.
Xenograft model
Stable LNCaP cells (2 Â 10 6 ) bearing LITAF shRNA or scrambled shRNA were resuspended in 100 ml phenol red-free RPMI medium and mixed with 100 ml matrigel (BD Biosciences, Bedford, MA, USA) for each injection. The cell suspensions were then injected subcutaneously into the flank of nude mice (Charles River Laboratories, Wilmington, MA, USA). Each group consisted of 10 mice and two spots were inoculated for each mouse. Ten days after inoculation, tumors were measured with calipers and tumor volume was calculated using the formula W 2 Â L/2 (W, shorter diameter; L, longer diameter) (mm 3 ).
For TNFSF15 administration, when tumors grew palpable, TNFSF15 prepared in phosphate buffer saline (100 ml, 10 mg/ml) or phosphate buffer saline as vehicle control was injected inside the tumors every 2 days. After 2 weeks injection, mice were euthanized and tumors removed and weighed.
Immunohistochemical staining procedures
Tumor tissues were snap-frozen and sectioned immediately or stored at À80 1C. The frozen sections were fixed with precooled acetone/methanol (1:1) fixative for 10 min at room temperature; endogenous peroxidase activity was quenched with 3% H 2 O 2 in methanol for 10 min. The slides were washed in Tris-buffered saline (TBS) three times, for 10 min each time, and blocked with 5% calf serum in TBS at room temperature for 1 h. They were then briefly rinsed with TBS and incubated with rabbit polyclonal antibodies against human Von Willebrand Factor (Catalog number, ab6994, Abcam, Cambridge, MA, USA) in 1:200 dilution with 5% calf serum-TBS at 4 1C overnight. Non-immunized rabbit IgG (Catalog number, I-1000, Vector Laboratories, Burlingame, CA, USA) was used as a negative control. The specimens were washed in TBS three times with gentle agitation and incubated with horseradish peroxide-conjugated anti-rabbit IgG antibodies (Catalog number, NEFB 12001EA, Perkin-Elmer, Covina, CA, USA) at room temperature for 1 h. After washing, the substrate 3,3-diaminobenzidine tetrahydrochloride (Catalog number, SK-4100, Vector Laboratories) was applied and signals were developed following the manufacturer's instruction. The specimens were counterstained with hematoxylin and dehydrated and mounted.
